- Details
- Thomas Keane highlights the PROfound Study, Olaparib for Metastatic Castrate Resistant Prostate Cancer , published in the New England Journal of Medicine this year. The study found that in men with metastatic prostate cancer with genetic alterations relating to homologous recombination repair who have shown disease progression while receiving ezalutamide or abiraterone, olaparib was associated wit...
|
- Details
- Thomas Keane reviews “Genomic Heterogeneity in Tissue-Based Prognostic Signatures from Prostate Biopsies: The Results from Two Prospective Trials” which was accepted for presentation at the virtual American Urological Association (AUA) 2020 meeting. Considering the challenge men with prostate cancer face in choosing between active surveillance and treatment, Dr. Keane discusses how the performance...
|
- Details
- Tom Keane, MD, discusses results presented at the virtual American Urological Association (AUA) 2020 meeting on biomarkers for prostate cancer, specifically assessing whether the 4Kscore biomarker, in addition to multiparametric MRI, could identify patients who would benefit from just a targeted biopsy. The data showed that 4Kscore in combination with multiparametric MRI can reduce unnecessary sys...
|
- Details
- Tom Keane discusses a presentation by Laurence Klotz given at the 2019 Société Internationale d'Urologie meeting on the topic of recent developments in imaging prior to a prostate biopsy. Dr. Klotz reviewed several studies comparing MRI to transrectal biopsies' effectiveness in detecting and ruling out clinically significant cancer. He also reviewed the PRECISION trial, which compared systemic bio...
|
- Details
- Tom Keane provides a comprehensive review of phase 2 KEYNOTE-057, assessing treatment with pembrolizumab for high-risk, non-muscle invasive bladder cancer in patients who are unresponsive to Bacillus Calmette (BCG), current standard of care in this patient population. Biography: Thomas E. Keane, MBBCh, FRCSI, FACS Related Content: Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMI...
|
- Details
- (Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...
|
- Details
- (Length of Discussion: 30 min) Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical applica...
|
- Details
- (Lenght of Discussion: 14 min) Tom Keane reviews three key presentations from the most recent American Urological Association (AUA) 2018 meeting. Among the presentations Keane discusses is a prostate cancer Imaging presentation by the Chief of MRI and Nuclear Medicine at the San Francisco VA Medical Center, Thomas Hope, MD. During his presentation, Prostate Cancer: What PET to GET? Hope discussed...
|
- Details
- (Length of Discussion: 16 min) Dr. Tom Keane discusses the rapidly changing landscape in advanced bladder cancer with the introduction of immune checkpoint inhibitors. To begin his discussion he references a presentation by Thomas Powles, MD from the 2018 ASCO GU meeting where Dr. Powles provided an overview of immune checkpoint inhibitors in urothelial carcinoma at the current time and Dr. Powles...
|
- Details
- (Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...
|
